Enlivex’s Allocetra shows sustained 12-month response in knee osteoarthritis patients aged 64 and older

• Enlivex announced favorable 12-month results from its Phase I/IIa Allocetra trial in moderate to severe knee osteoarthritis.
• A single treatment cycle sustained pain relief and improved knee function through one year, with greater clinical response than placebo in patients 64+.
• No treatment-related serious adverse events occurred; adverse events were predominantly temporary, mild to moderate local knee reactions.
• The results will be presented at the American College of Rheumatology Convergence on November 8, 2026.
• The ongoing Phase IIb trial targets the same older population, with topline results expected by the end of the second quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020800PRIMZONEFULLFEED9867916) on November 02, 2026, and is solely responsible for the information contained therein.